After Catalent (CTLT) announced productivity issues with the company’s gene manufacturing facility in Maryland, BofA points out that the company noted they do not expect the problems related to the deployment of a new enterprise resource planning system to impact the quality of commercial launch supply for any gene therapy product. BofA further connected with Sarepta (SRPT), which has an agreement with Catalent for SRP-9001, and Sarepta’s management reiterated that they do not expect any impact on the production or planned launch of SRP-9001, the firm tells investors. BofA maintains a Buy rating and $164 price target on Sarepta shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Morgan Stanley still expects Sarepta to get approval for SRP-9001
- Sarepta approval still likely despite STAT article, says William Blair
- Wave Life selloff on Sarepta article ‘makes no sense,’ says Mizuho
- Opco says buy Sarepta on selloff, views unchanged after article
- Sarepta volatility ‘name of the game’ into AdCom and PDUFA date, says Guggenheim